Long-acting FSH analogue: Corifollitropin-α to sustain multifollicular growth during controlled ovarian stimulation

References

• Boivin J, Bunting L, Collins JA, Nygren KG. International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care. Hum. Reprod.22, 1506–1512 (2007).
   PubMed Web of Science ®Google Scholar
• Van Santbrink EJ, Hop WC, van Dessel TJ, de Jong FH, Fauser BCJM. Decremental follicle-stimulating hormone and dominant follicle development during the normal menstrual cycle. Fertil. Steril.64, 37–43 (1995).
   PubMed Web of Science ®Google Scholar
• Sullivan MW, Stewart-Akers A, Krasnow JS, Berga SL, Zeleznik AJ. Ovarian responses in women to recombinant follicle-stimulating hormone and luteinizing hormone (LH): a role for LH in the final stages of follicular maturation. J. Clin. Endocrinol. Metab.84, 228–232 (1999).
   PubMed Web of Science ®Google Scholar
• Fiddes JC, Talmadge K. Structure, expression, and evolution of the genes for the human glycoprotein hormones. Recent Prog. Horm. Res.40, 43–78 (1984).
   PubMedGoogle Scholar
• Lalloz MR, Detta A, Clayton RN. Gonadotropin-releasing hormone desensitization preferentially inhibits expression of the luteinizing hormone β-subunit gene in vivo. Endocrinology122(4), 1689–1694 (1988).
   PubMed Web of Science ®Google Scholar
• Nisula BC, Blithe DL, Akar A, Lefort G, Wehmann RE. Metabolic fate of human choriogonadotropin. J. Steroid Biochem.33(4B), 733–737 (1989).
   PubMedGoogle Scholar
• Ulloa-Aguirre A, Timossi C, Damián-Matsumura P, Dias JA. Role of glycosylation in function of follicle-stimulating hormone. Endocrine11(3), 205–215 (1999).
   PubMed Web of Science ®Google Scholar
• Kohler PO, Ross GT, Odell WD. Metabolic clearance and production rates of human luteinizing hormone in pre- and post-menopausal women. J. Clin. Invest.47, 38–47 (1968).
   PubMed Web of Science ®Google Scholar
• Stockell-Hartree A, Renwick AG. Molecular structures of glycoprotein hormones and functions of their carbohydrate components. Biochem. J.287, 665–679 (1992).
   PubMed Web of Science ®Google Scholar
• Fauser BCJM, Mannaerts BMJL, Devroey P, Leader A, Boime I, Baird DT. Advances in recombinant DNA technology: corifollitropin-α, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency. Hum. Reprod. Update15(3), 309–321 (2009).
   PubMed Web of Science ®Google Scholar
• Birken S, Canfield RE. Isolation and amino acid sequence of COOH-terminal fragments from the b subunit of human choriogonadotropin. J. Biol. Chem.252, 5386–5392 (1977).
   PubMed Web of Science ®Google Scholar
• Kessler MJ, Mise T, Ghai RD, Bahl OP. Structure and location of the O-glycosidic carbohydrate units of human chorionic gonadotropin. J. Biol. Chem.254, 7909–7914 (1979).
   PubMed Web of Science ®Google Scholar
• VanWely M and Van der Veen F. Meta-analysis of recombinant FSH and urinary-derived gonadotropins for IVF or ICSI. Hum. Reprod.18, 1554–1555 (2003).
   PubMedGoogle Scholar
• Mannaerts BMJL, Shoham Z, Schoot D et al. Single-dose pharmacokinetics and pharmacodynamics of recombinant human follicle-stimulating hormone (Org 32849) in gonadotropin-deficient volunteers. Fertil. Steril.59, 108–114 (1993).
   PubMed Web of Science ®Google Scholar
• Beckers NGM, Macklon NS, Devroey P, Platteau P, Boerrigter PJ, Fauser BCJM. First live birth after ovarian stimulation using a chimeric long-acting human recombinant follicle-stimulating hormone (FSH) agonist (recFSH-CTP) for in vitro fertilization. Fertil. Steril.79, 621–623 (2003).
   PubMed Web of Science ®Google Scholar
• Boime I, Keene J, Galway AB and Fares FM. Expression of recombinant human FSH, LH and CG in mammalian cells, a structure-function model for therapeutic drug design. Semin. Reprod. Endocrinol.10, 45–50 (1990).
   Google Scholar
• Fares FA, Suganuma N, Nishimori K, LaPolt PS, Hsueh AJ, Boime I. Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin b subunit to the follitropin b subunit. Proc. Natl Acad. Sci. USA89, 4304–4308 (1992).
   PubMed Web of Science ®Google Scholar
• Boime I, Ben-Menahem D. Glycoproteing hormone structure-function and analog design. Recent Prog. Horm. Res.54, 288–289 (1999).
   Google Scholar
• LaPolt P, Nishimori K, Fares FA, Perlas E, Boime I, Hsueh AJ. Enhanced stimulation of follicle maturation and ovulatory potential by long acting follicle-stimulating hormone agonists with extended carboxyl-terminal peptides. Endocrinology131(6), 2514–2520 (1992).
   PubMed Web of Science ®Google Scholar
• Donini P, Montezemolo R. Rassegna di Clinica, Terapia e Scienze Affini. In: A Publication of the Biologic Laboratories of the Instituto Serono, 48. Serono Pharmaceutical Research Institute, SA, USA 3–28 (1949).
   Google Scholar
• Howles CM, Loumaye E, Giroud D, Luyet G. Multiple follicular development and ovarian steridogenesis following subcutaneous administration of a highly purified urinary FSH preparation in pituitary desensitized women undergoing IVF: a multicentre European Phase III study. Hum. Reprod.9, 424–430 (1994).
   PubMed Web of Science ®Google Scholar
• Lunenfeld B. Development of gonadotrophins for clinical use. Reprod. Biomed. Online4(Suppl. 1), 11–17 (2002).
   PubMedGoogle Scholar
• Hayden CJ, Balen AH, Rutherford AJ. Recombinant gonadotrophins. Br. J. Obstet. Gynaecol.106(3), 188–196 (1999).
   PubMedGoogle Scholar
• Bouloux PM, Handelsman DJ, Jockenhövel F et al.; FSH–CTP Study Group. First human exposure to FSH–CTP in hypogonadotrophic hypogonadal males. Hum. Reprod.16, 1592–1597 (2001).
   PubMed Web of Science ®Google Scholar
• Duijkers IJ, Klipping C, Boerrigter PJ, Machielsen CS, De Bie JJ, Voortman G. Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH–CTP) in healthy pituitary-suppressed females. Hum. Reprod.17, 1987–1993 (2002).
   PubMed Web of Science ®Google Scholar
• The corifollitropin a Dose-finding Study Group. A randomized dose–response trial of a single injection of corifollitropin-α to sustain multifollicular growth during controlled ovarian stimulation. Hum. Reprod.23, 2484–2492 (2008).
   PubMed Web of Science ®Google Scholar
• Balen AH, Mulders AG, Fauser BCJM et al. Pharmacodynamics of a single low dose of long-acting recombinant follicle-stimulating hormone (FSH–carboxy terminal peptide, corifollitropin-α) in women with World Health Organization group II anovulatory infertility. J. Clin. Endocrinol. Metab.89, 6297–6304 (2004).
   PubMed Web of Science ®Google Scholar
• De Greef R, Struijs M, de Haan A, Marintcheva-Petrova M, Mannaerts BMJL. Dose selection of Org 36286 (corifollitropin-α) using pharmacokinetic and dynamic modeling and simulation. Hum. Reprod.22, I39 (2007) (Abstract O-099).
   Google Scholar
• Fatemi HM, Popovic-Todorovic B, Papanikolaou E, Donoso P, Devroey P. An update of luteal phase support in stimulated IVF cycles. Hum. Reprod. Update13(6), 581–590 (2007).
   PubMed Web of Science ®Google Scholar
• Daya S. Gonadotropin releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gamete intrafallopian transfer cycles. Cochrane Database Syst. Rev. (2), CD001299 (2000).
   Google Scholar
• Griesinger G, Diedrich K, Devroey P, Kolibianakis EM. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum. Reprod. Update.12(2), 159–168 (2006).
   PubMed Web of Science ®Google Scholar
• Humaidan P, Bungum L, Bungum M, Yding AC. Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reprod. Biomed. Online13, 173–178 (2006).
   PubMed Web of Science ®Google Scholar
• Humaidan P, Bredkjær HE, Westergaard LG, Yding AC. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil. Steril. DOI: 10.1016/j.fertnstert.2008.12.042 (2009) (Epub ahead of print).
   Google Scholar
• Engmann L, Diluigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil. Steril.89, 84–91 (2008).
   PubMed Web of Science ®Google Scholar